Welcome!

News Feed Item

2013 US Hospital Cancer Diagnostics Market

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

2013 US Hospital Cancer Diagnostics Market

http://www.reportlinker.com/p01079355/2013-US-Hospital-Cancer-Diagnostics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

This new report from Venture Planning Group contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital cancer diagnostics market, including: 

  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years. 
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. 
  • Test volume and sales forecasts for 40 cancer diagnostic procedures performed in US hospitals.  
  • Current instrumentation technologies and feature comparison of leading analyzers. 
  • Sales and market shares of  leading suppliers. 
  • Emerging diagnostic technologies and their potential market applications. 
  • Product development opportunities. 
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. 
  • Business opportunities and strategic recommendations for suppliers. 

         Contains 567 pages and 50 tables

Table of Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. Brest Cancer

2. Lung Cancer

3. Colon and Rectum Cancer

4. Prostate Cancer

5. Stomach Cancer

6. Leukemia

7. Lymphoma

8. Oral Cancer

9. Skin Cancer

10. Uterine Cancer

11. Ovarian Cancer

12. Bladder Cancer

B. Major Current And Emerging Cancer Diagnostic Tests

1. Introduction

2. Tumor Marker Classification

3. ACTH

4. Alpha-Fetoprotein (AFP)

5. Beta-2 Microglobulin

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. Calcitonin

10. Carcinoembrionic Antigen (CEA)

11. Estrogen and Progesterone Receptors

12. Ferritin

13. Gastrin

14. Human Chorionic Gonadotropin (HCG)

15. Insulin

16. NSE

17. Occult Blood

18. PAP Smear/HPV

19. Prostatic Acid Phosphatase (PAP)

20. Prostate-Specific Antigen (PSA)

21. Squamous Cell Carcinoma Antigen (SCC)

22. T and B Lymphocytes

23. TdT

24. Thyroglobulin

25. Tissue Polypeptide Antigen (TPA)

26. Biochemical Tumor Markers

- ADA

- B-Protein

- PNP

- 5'-Nucleotidase

27. Oncogenes

- Abl/abl-bcr

- AIB1

- BCL-2

- BRCA1

- CD44

- C-fos

- C-myb

- C-myc

- CYP-17

- Erb-B

- HPC1

- N-myc

- P40

- P51

- P53

- PIK3CA

- PTI-1

- Ras

- Reg

- Sis

- Src

28. Polypeptide Growth Factors

- Basic Fibroblast Growth Factor

- Beta-TGF

- Cachectin (TNT)

- Calmodulin

- ECFR

- Nerve Growth Factor (NGF)

- Epidermal Growth Factor (EGF)

- Ornithine Decarboxylase

- Transferrin

- Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

- Alpha-Interferon

- B Cell Growth Factors

- B Cell Growth Factor (BCGF)

- Gamma-Interferon

- Interleukin-1 (IL-1)

- Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

- N-Acetylglucosamine

- Actin

- Alpha-Actin

- Antineuronal Antibodies

- 7B2

- B72.3

- Bax

- BCD-F9

- BLCA-4

- Blood Group Antigens A,B,H

- CA 50

- CA 72-4/TAG-72

- CA 195

- CA-242

- CA-549

- CAM 26

- CAR-3

- Cathepsin-D

- Chromogranin A and B

- Cluster 1 Antigen

- Cluster-5/5A Antigen

- CTA

- CU18

- DR-70

- DU-PAN-2

- Endometrial Bleeding Associated Factor

- Endostatin

- Epithelial Membrane Antigen

- Feulgen Hydrolysis

- Fibronectin

- FSH

- (1->3)-L-fucosyltransferase

- Gastrin-Releasing Peptide (GRP)

- GDCFP-15

- Glucagon

- Glycoamines

- H23

- Her-2

- Human Carcinoma Antigen

- HPA

- HSP27

- Intermediate Filaments

- Cytokeratins/CK18/Cyfra 21-1

- Desmin

- Gliofibrillary Acid Protein

- Neurofilaments

- Vimentin

- KA 93

- Kinases

- KP16D3

- LAI

- Leukocyte Common Antigen

- Lewis Antigens

- Lysophosphatidic Acid (LPA)

- Ma 695/Ma 552

- MABDF3

- MAG

- ME1

- Minactivin

- MN/CA9

- MSA

- Mucin Cancer Antigen (MCA)

- Multiple Tumor Suppressor 1

- Myosin

- NEA-130

- NMP22

- OA-519

- Opiod Peptides

- P-glycoprotein

- Pancreatic Oncofetal Antigen (POA)

- Placental Lactogen

- PR92

- Proliferative Index, Ki-67

- Px

- RB Inactivation/Deletion

- Ret

- SCCL 175

- Selectin

- Sialic Acid

- Sialyl SSEA-1/SLX

- SN10

- Somatostatin

- TA-90

- TABA

- Tachykinin

- TAG 12

- TPS

- Troponin

- Tubulin

- VCAM

- VEGF

- Villen

C. Instrumentation Review

And Market Needs

1. Abbott AxSYM

2. Abbott Architect c4000

3. Abbott Architect i2000 Series

4. Abbott Architect ci8200 System

5. Beckman Coulter UniCel Series

6. Beckman Coulter Access

7. Binding Site ESP600

8. bioMerieux Mini Vidas

9. Carolina Chemistries BioLis 24i

10. DiaSorin Liaison

11. Horiba ABX Pentra 400

12. Inverness DS2

13. J&J Vitros ECi/ECiQ

14. J&J Vitros 3600

15. J&J Vitros 5600

16. Olympus AU5400

17. Olympus AU3000i

18. Olympus AU2700

19. Roche Modular Analytics

20. Roche Cobas Integra 400

21. Roche Cobas Integra 400 Plus

22. Roche Elecsys

23. Roche Cobas c311

24. Siemens ADVIA Centaur

25. Siemens Dimension

26. Siemens Dimension RxL Max

27. Siemens Dimension Vista 500

28. Siemens Immulite

29. Siemens Stratus

30. Tosoh AIA-Series

31. Vital Diagnostics ATAC 8000

32. Vital Diagnostics Envoy 500

D. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

- Overview

- ELISA

- Immunofiltration

- Particle-Membrane Capture Immunoassay

- Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

- Chemiluminescence

- Bioluminescence

f. Latex Agglutination

g. Immunoprecipitation

H. Affinity Chromatographu

e. Liposome Flow-Injection Immunoassay

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

- PCR

- DAP-PCR

- Immuno-PCR

- QC-PCR

- CAR

- DNA

- HPA

- LCR

- NASBA

- QBR

- SDA

- 3 SR, and others

4. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

g. Chromosomal Translocation and Oncogenes

5. Artificial Intelligence

6. Flow Cytometry

7. Two Dimensional Gel Electrophoresis (2-DGE)

8. Biosensors

9. Competing/Complementing Technologies

a. CT

b. MRI

c. NMR

d. PET

e. Photonics Spectroscopy

E. Personal Testing

U.S.A.

A. Executive Summary

B. Business Environment

1. Health Care Expenditures

2. Cost Consciousness

3. Industry Consolidation

4. Managed Care

5. Hospitals

6. Admissions

7. Length of Stay

8. Industry Diversification

9. Physician Demographics

10. Population Aging

a. Chronic Illness

b. Disease Incidence

c. Susceptibility to Iatrogenesis

d. Multiple Illness Cases

11. Laboratory Regulations

C. Market Structure

1. Centralized Testing

a. Hospitals

b. Commercial/Private Laboratories

2. POT/Decentralized Testing

a. Physician Offices/Group Practices

b. Cancer Clinics

c. Point-Of-Care Testing

d. Other Decentralized Testing Locations

D. Market Size, Growth and Major Suppliers Sales,

Instrument Placements and Market Shares

Major Product Development Opportunities

A. Reagent Kits and Test Systems/Panels

B. Instrumentation

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Profiles

- Abbott

- AdnaGen

- Applied Gene Technologies

- Arca

- Beckman Coulter/Danaher

- Becton Dickinson

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Cepheid

- Correlogic Systems

- Dako

- Decode

- Diadexus

- Diagnocure

- Diasorin

- Eiken Chemical

- Enterix

- Enzo Biochem

- Epigenomics

- Exact Sciences

- Fujirebio

- Gen-Probe

- Guided Therapeutics

- Hologic

- Ipsogen

- Kreatech

- Kyowa Medex

- Life Technologies

- Mackay Life Sciences

- Myriad Genetics

- Nanogen Elitech

- OncoLab

- Otho-Clinical Diagnostics

- Panacea Pharmaceuticals

- Polartechnics

- Polymedco

- PreMD

- Qiagen

- Radient Pharmaceuticals

- Roche

- Scienion

- Sequenom

- Siemens Healthcare

- Takara Bio

- Targeted Diagnostics & Therapeutics

- Tosoh

- Veridex

- Wako Pure Chemicals

- Wallac/PE

- Zila

List of Tables

Tumor Marker Classification

Major Companies Developing or Marketing

ACTH Tests

Major Companies Developing or Marketing

AFP Tests

Major Companies Developing or Marketing

Beta-2 Microglobulin Tests

Major Companies Developing or Marketing

CA 15-3/27.29 Tests

Major Companies Developing or Marketing

CA 19-9 Tests

Major Companies Developing or Marketing

CA 125 Tests

Major Companies Developing or Marketing

Calcitonin Tests

Major Companies Developing or Marketing

CEA Tests

Major Companies Developing or Marketing

Estrogen Receptor Tests

Major Companies Developing or Marketing

Progesterone Receptor Tests

Major Companies Developing or Marketing

Ferritin Tests

Major Companies Developing or Marketing

Gastrin Tests

Major Companies Developing or Marketing

HCG Tests

Major Companies Developing or Marketing

Insulin Tests

Major Companies Developing or Marketing

NSE Tests

Major Companies Developing or Marketing

Occult Blood Tests

Major Companies Developing or Marketing

PAP Smear/HPV Tests

Major Companies Developing or Marketing

PAP Tests

Major Companies Developing or Marketing

PSA Tests

Major Companies Developing or Marketing

Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications

In Cancer Diagnosis

Oncogenes Potential Applications

In Cancer Diagnosis

Major Companies Developing or Marketing

Oncogene Tests

Growth Factors Potential Applications

In Cancer Diagnosis

Colony Stimulating Factors Potential

Applications in Cancer Diagnosis

Lymphokines Potential Applications

In Cancer Diagnosis

Immunohistochemical Stains Potential

Applications in Cancer Diagnosis

Executive Summary Table: U.S., Hospital

Cancer Diagnostic Test Volume and Sales Forecast

U.S., Estimated New Cancer Cases and Deaths

U.S., Estimated Cancer Death Rates

Per 100,000 Population

U.S., Laboratories Performing Cancer Diagnostic

Tests

U.S., Hospital Laboratories Performing

Cancer Diagnostics Tests by Bed Size

U.S., Hospital Laboratories Major Cancer

Diagnostic Test Volume Forecast by Test

U.S., Total Cancer Diagnostics Sales

By Major Supplier

U.S., ACTH Testing Market Diagnostics

Sales by Major Supplier

U.S., AFP Testing Market Diagnostics

Sales by Major Supplier

U.S., Beta-2 Migroblolulin Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 15-3/27.29 Testing Market

Diagnostics Sales by Major Supplier

U.S., CA 19-9 Testing Market Diagnostics

Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics

Sales by Major Supplier

U.S., CEA Testing Market Diagnostics

Sales by Major Supplier

U.S., Ferritin Testing Market

Diagnostics Sales by Major Supplier

U.S., HCG Testing Market

Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market

Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing

Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics

Sales by Major Supplier

U.S., Progesterone Receptor Testing Market

Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics

Sales by Major Supplier

To order this report:

Diagnostics Industry: 2013 US Hospital Cancer Diagnostics Market

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band-aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It does...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
The WebRTC Summit New York, to be held June 6-8, 2017, at the Javits Center in New York City, NY, announces that its Call for Papers is now open. Topics include all aspects of improving IT delivery by eliminating waste through automated business models leveraging cloud technologies. WebRTC Summit is co-located with 20th International Cloud Expo and @ThingsExpo. WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web ...